Participants maintaining mean hemoglobin (Hb) concentration within the target range i.e. 10.0 - 12.0 gram per deciliter (g/dL) during last 4 weeks (Weeks 8 to 12) of treatment period (TP) were reported. Total duration for treatment period was 12 weeks. Stability verification period of 2-weeks was conducted before treatment period. The reference Hb concentrations were based upon the mean of the assessments at Weeks -2, -1 and Week 0. The target range for assessment was set at the reference value Hb +/- 1 g/dL but not >12.0 g/dL and not <10.0 g/dL.

Per-protocol (PP) population comprised of participants who had received at least 1 dose of MIRCERA (Week 0) and for whom data for at least one follow-up variable was available and who had completed the study.

The mean change in Hb concentration between reference stability verification period (SVP) and in last 4 weeks (Weeks 8 to 12) of treatment period (TP) was reported. Duration for SVP was 2 weeks followed by treatment period of 12 weeks. The reference Hb concentrations were based upon the mean of the assessments at Weeks -2, -1 and Week 0. The target range for assessment was set at the reference value hemoglobin +/- 1 g/dL but not >12.0 g/dL and not <10.0 g/dL.

Per-protocol (PP) population comprised of participants who had received at least 1 dose of MIRCERA (Week 0) and for whom data for at least one follow-up variable was available and who had completed the study.

Mean time participants spent having hemoglobin range of 10.0 to 12.0 g/dL was reported. The reference Hb concentrations were based upon the mean of the assessments at Weeks -2, -1 and Week 0. The target range for assessment was set at the reference value hemoglobin +/- 1 gram per deciliter but not >12.0 g/dL and not <10.0 g/dL.

Per-protocol (PP) population comprised of participants who had received at least 1 dose of MIRCERA (Week 0) and for whom data for at least one follow-up variable was available and who had completed the study.

Participants with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and deaths in the overall study were reported. An Adverse Event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Safety population included all enrolled participants who received at least one dose of study drug.

Mean change from Baseline (Week -1) to end of the treatment (Week 12) in heart rate was reported. Baseline measure was considered as (Week -1) evaluation for this parameter.

Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.

Mean change from Baseline (Week -2) to end of the treatment (Week 12) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) before and after dialysis was reported. Baseline measure was considered as (Week -2) evaluation for this parameter.

Safety population included all enrolled participants who received at least one dose of study drug. n = the number of participants analyzed at a given time point.

Participants with abnormal electrocardiogram were reported.

Safety population included all enrolled participants who received at least one dose of study drug. n = the number of participants analyzed at a given time point.

Mean values of white blood cells (WBCs), and platelets at Weeks -2, 4, 8, and 12 were reported.

Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.

Mean values of hypochromic red blood cells (RBCs) at Weeks -2, 4, 8, and 12 were reported.

Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.

Mean corpuscular volume (MCV) is a measure of the average red blood cell volume. MCV levels at Weeks -2, 4, 8, and 12 were reported.

Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.

Mean values of serum iron and total iron binding capacity (TIBC) were reported.

Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.

Mean values of serum ferritin were reported.

Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.

Mean values of transferrin were reported.

Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.

Mean values of Transferrin Saturation (TSAT) were reported.

Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.

Mean values of serum albumin and serum globulin were reported.

Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.

Mean values of aspartate aminotransferase (AST), alanine transaminase (ALT) and serum alkaline phosphatase were reported.

Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.

Mean values of serum creatinine, blood urea nitrogen (BUN), serum phosphate and serum bilirubin were reported.

Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.

Mean values of serum sodium and serum potassium were reported.

Safety population included all enrolled participants who received at least one dose of study drug. n = number of participants analyzed at a given time point.